These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36275783)

  • 21. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
    Poulose JV; Kainickal CT
    World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
    Mollica V; Rizzo A; Di Nunno V; Santoni M; Cheng L; Lopez-Beltran A; Scarpelli M; Cimadamore A; Montironi R; Massari F
    Transl Androl Urol; 2021 Mar; 10(3):1581-1587. PubMed ID: 33850792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement.
    Lalani AA; Kapoor A; Basappa NS; Bhindi B; Bjarnason GA; Bosse D; Breau RH; Canil CM; Cardenas LM; Castonguay V; Chavez-Munoz C; Chu W; Dudani S; Graham J; Heng DYC; Kollmannsberger C; Lattouf JB; Morgan S; Reaume MN; Richard PO; Swaminath A; Tanguay S; Wood LA; Lavallée LT
    Can Urol Assoc J; 2023 May; 17(5):E154-E163. PubMed ID: 37185210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience.
    De Gobbi A; Biasoni D; Catanzaro M; Nicolai N; Piva L; Stagni S; Torelli T; Procopio G; Verzoni E; Grassi P; Colecchia M; Paolini B; Spreafico C; Marchianò A; Salvioni R
    Tumori; 2018 Oct; 104(5):388-393. PubMed ID: 28085177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis.
    Chierigo F; Wenzel M; Würnschimmel C; Flammia RS; Horlemann B; Tian Z; Saad F; Chun FKH; Tilki D; Shariat SF; Gallucci M; Borghesi M; Suardi N; Terrone C; Karakiewicz PI
    Crit Rev Oncol Hematol; 2022 Jan; 169():103534. PubMed ID: 34823022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date.
    Tacconi EMC; Tuthill M; Protheroe A
    Onco Targets Ther; 2020; 13():12301-12316. PubMed ID: 33299326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
    Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
    Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
    Choueiri TK; Tomczak P; Park SH; Venugopal B; Ferguson T; Chang YH; Hajek J; Symeonides SN; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Gurney H; Chevreau C; Melichar B; Kopyltsov E; Alva A; Burke JM; Doshi G; Topart D; Oudard S; Hammers H; Kitamura H; Bedke J; Perini RF; Zhang P; Imai K; Willemann-Rogerio J; Quinn DI; Powles T;
    N Engl J Med; 2021 Aug; 385(8):683-694. PubMed ID: 34407342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials.
    Messina C; Zanardi E; Boccardo F
    Anticancer Agents Med Chem; 2017; 17(12):1633-1643. PubMed ID: 28270065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EORTC-GU group expert opinion on metastatic renal cell cancer.
    de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
    Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives.
    Larroquette M; Peyraud F; Domblides C; Lefort F; Bernhard JC; Ravaud A; Gross-Goupil M
    Cancer Treat Rev; 2021 Jun; 97():102207. PubMed ID: 33906023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
    Chamie K; Donin NM; Klöpfer P; Bevan P; Fall B; Wilhelm O; Störkel S; Said J; Gambla M; Hawkins RE; Jankilevich G; Kapoor A; Kopyltsov E; Staehler M; Taari K; Wainstein AJA; Pantuck AJ; Belldegrun AS
    JAMA Oncol; 2017 Jul; 3(7):913-920. PubMed ID: 27787547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
    Capitanio U; Fallara G; Raggi D; Nocera L; Larcher A; Belladelli F; Rowe I; Briganti A; Salonia A; Karakiewicz P; Montorsi F; Martini A; Necchi A
    Curr Probl Cancer; 2022 Aug; 46(4):100875. PubMed ID: 35679628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature.
    Bandini M; Smith A; Marchioni M; Pompe RS; Martel TF; Cindolo L; Montorsi F; Shariat SF; Briganti A; Kapoor A; Capitanio U; Karakiewicz PI
    Clin Genitourin Cancer; 2018 Jun; 16(3):176-183. PubMed ID: 29449091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
    Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
    Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
    Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
    BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Martinez Chanza N; Tripathi A; Harshman LC
    Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
    Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
    Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.